Hepatic fibrosis is the common pathological basis of various chronic liver diseases.Liver biopsy remains the gold standard for the assessment and diagnosis of liver fibrosis,but its invasiveness and high requirements for operation limit its clinical application.This article introduces the development of noninvasive diagnosis of hepatic fibrosis,such as serological and imaging techniques.However,these methods cannot completely replace liver biopsy.Therefore,a comprehensive noninvasive diagnosis model for hepatic fibrosis has become a research hotspot.

In recent years, new changes have occurred in the treatment of chronic hepatitis C. Direct-acting antiviral agents have shown powerful efficacy in the treatment of active hepatitis C, and even refractory hepatitis C shows a high continuous virologic response. Among these direct-acting antiviral agents, sofosbuvir (SOF) has the advantages of short course of antiviral treatment and high response rate, and some patients with certain hepatitis C genotypes have no need to receive interferon therapy. This article introduces the mechanism of action, current status of clinical application, and major adverse effects of SOF, and points out its promising future in patients with refractory hepatitis C.